Table 1.
Demographic and clinico-pathological characteristics of patients with MDS (n = 114).
| Characteristic | N (%)a |
|---|---|
| Age category | |
| 65–69 | 34 (29.8) |
| 70–74 | 35 (30.7) |
| 75–79 | 22 (19.3) |
| 80+ | 23 (20.2) |
| Male | 85 (74.6) |
| White | 108 (94.7) |
| Lives alone | 13 (11.8) |
| History of tobacco use | 65 (57.0) |
| WHO BMI categories | |
| <25 | 30 (27.1) |
| 25–30 | 48 (43.2) |
| >30 | 33 (29.7) |
| Baseline ECOG Performance Status | |
| 0 | 51 (44.7) |
| 1 | 49 (43.0) |
| ≥2 | 14 (12.3) |
| Baseline Charlson comorbidity score | |
| 0 | 43 (37.7) |
| 1 | 19 (16.7) |
| 2 | 30 (26.3) |
| ≥3 | 22 (19.3) |
| Serum albumin <3.5 g/dl | 11 (9.7) |
| Number of cytopeniasd | |
| 0 | 16 (14.0) |
| 1 | 36 (31.6) |
| 2 | 39 (34.2) |
| 3 | 23 (20.2) |
| Cytogeneticse | |
| Good | 76 (66.6) |
| Intermediate | 19 (16.7) |
| Poor | 19 (16.7) |
| % Bone marrow blastsf | |
| <5% | 74 (66.1) |
| 5–10% | 27 (24.1) |
| >10% | 11 (9.8) |
| IPSS Category | |
| Low risk | 27 (23.7) |
| Intermediate risk-1 | 52 (45.6) |
| Intermediate risk-2 | 30 (26.3) |
| High risk | 5 (4.4) |
| Previous chemotherapy or radiation | 20 (17.5) |
| Treatment type received | |
| No chemotherapy | 53 (46.5) |
| Non-intensive chemotherapyb | 44 (38.6) |
| Intensive chemotherapyc | 17 (14.9) |
a
May not add up to 100% due to missing variables.
b
5-Azacytidine or decitabine.
c
Induction chemotherapy and/or non-myeloablative bone marrow transplant.
d
Component of the IPSS score. Platelets < 100,000/μl; hemoglobin < 10 g/dl; neutrophils < 1800/μl.
e
Component of the IPSS score. Good: normal, -Y, del(5q), del(20q); intermediate: other abnormalities; poor: complex (≥3 abnormalities) or chromosome 7 anomalies.
f
Component of the IPSS score.